Condition: Heart Failure · Sponsor: Carmat SAS
The safety and performance of the Aeson TAH system have been demonstrated for the CE mark approval in December 2020. The purpose of this post-market clinical investigation is to confirm the safety, performance and effectiveness of the Aeson TAH system when used in routine care by surgeons.
This description comes directly from the study's public registry record.
Elisabeth Vacher · +33 6 34 92 86 84 · Elisabeth.Vacher@carmatsas.com
Piet Jansen · +33 6 46 06 07 12 · piet.jansen@carmatsas.com
Always discuss trial participation with your own doctor first.
| HZ Dresden | Dresden, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05474092